DNA damage response inhibitors are a promising cancer therapy. Here, the authors show that combined PARP and ATR inhibition triggers ZBP1-dependent PANoptosis in cancer and normal cells, revealing a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback